daratumumab

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger
Endpoints
Genmab
daratumumab
Darzalex
Multiple Myeloma
clinical trials
Flag link:
Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space
Johnson & Johnson Courting Huge Revenue Potential In Multiple Myeloma Space
Seeking Alpha
JNJ
Multiple Myeloma
daratumumab
ASCO 2016
Flag link:
Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Johnson & Johnson's Latest FDA Approval Could Spell Problems for Amgen
Motley Fool
JNJ
FDA
Amgen
Darzalex
daratumumab
Multiple Myeloma
Flag link:
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex
Fierce Biotech
JNJ
Multiple Myeloma
daratumumab
FDA
Darzalex
Genmab
Flag link:
4 Things Johnson & Johnson Should Address When it Reports Its Q3 Results
4 Things Johnson & Johnson Should Address When it Reports Its Q3 Results
Motley Fool
JNJ
earnings
Invokana
daratumumab
devices
Flag link:
Bristol-Myers, J&J Upgraded On New Drug Prospects
Bristol-Myers, J&J Upgraded On New Drug Prospects
Investors.com
Bristol-Myers Squibb
JNJ
Imbruvica
Opdivo
daratumumab
Flag link:
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
J&J positions blockbuster contender daratumumab for a multiple myeloma showdown
Fierce Biotech
JNJ
daratumumab
Multiple Myeloma
Kyprolis
Amgen
Genmab
elotuzumab
AbbVie
Bristol-Myers Squibb
Flag link:
Is This Johnson & Johnson's Next Blockbuster?
Is This Johnson & Johnson's Next Blockbuster?
Investopedia
JNJ
Multiple Myeloma
daratumumab
Flag link:
Genmab shares rise on cancer drug's FDA license application
Genmab shares rise on cancer drug's FDA license application
Yahoo/Reuters
Genmab
FDA
JNJ
daratumumab
Multiple Myeloma
Flag link:
Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J
Your ASCO15 guide: A mixed bag for Bristol-Myers, big wins for Merck, J&J
BioPharma Dive
ASCO
Bristol-Myers Squibb
JNJ
Merck
Keytruda
Opdivo
daratumumab
Flag link:
J&J multiple myeloma drug offers hope after others stop working -study
J&J multiple myeloma drug offers hope after others stop working -study
Yahoo/Reuters
JNJ
Multiple Myeloma
ASCO
daratumumab
Flag link:
JNJ launches PhII lymphoma study for daratumumab
JNJ launches PhII lymphoma study for daratumumab
Fierce Biotech
JNJ
lymphoma
daratumumab
Genmab
non-Hodgkin's lymphoma
Flag link:
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
Genmab Announces Phase III Study of Daratumumab in Front Line Multiple Myeloma
Pipeline Review
daratumumab
Multiple Myeloma
Flag link:
J&J hands over $25M milestone for daratumumab progress
J&J hands over $25M milestone for daratumumab progress
Fierce Biotech
JNJ
daratumumab
Genmab
Flag link:
Milestone payment triggers Genmab guidance increase
Milestone payment triggers Genmab guidance increase
Yahoo/Reuters
Genmab
daratumumab
JNJ
Janssen
Flag link:
These 2 Companies Are the Biggest Winners of the FDA's Breakthrough Designation
These 2 Companies Are the Biggest Winners of the FDA's Breakthrough Designation
Motley Fool
FDA
breakthrough therapies
ibrutinib
Pharmacyclics
JNJ
Novartis
LDK378
serelaxin
daratumumab
Genmab
Flag link:
What Does The FDA's Breakthrough Designation Mean For Investors?
What Does The FDA's Breakthrough Designation Mean For Investors?
Seeking Alpha
FDA
breakthrough therapies
AbbVie
Alexion
Ariad Pharmaceuticals
Biomarin
Bristol-Myers Squibb
SynaGeva BioPharma
GSK
JNJ
Merck
Novartis
Pharmacyclics
Pfizer
Vertex Pharmaceuticals
daratumumab
ibrutinib
Kalydeco
lambrolizumab
palbociclib
LDK378
SD-101
obinutuzumab
serelaxin
asfotase alfa
bimagrumab
drisapersen
sebelipase alfa
Flag link:
Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors
Johnson & Johnson's Potential Blockbuster For Multiple Myeloma And Its Competitors
Seeking Alpha
JNJ
Multiple Myeloma
daratumumab
Genmab
Flag link:
Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug
Genmab Rises After FDA Grants Breakthrough Status to Cancer Drug
Bloomberg
Genmab
FDA
JNJ
daratumumab
Multiple Myeloma
Flag link:
Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover
Genmab Rises as Nordea Says Bet on Cancer Drug: Copenhagen Mover
Bloomberg
Genmab
JNJ
daratumumab
Multiple Myeloma
Flag link: